In Vitro Activity of Tebipenem, a New Oral Carbapenem Antibiotic, against Penicillin-Nonsusceptible Streptococcus pneumoniae

Reiko Kobayashi,1 Mami Konomi,2 Keiko Hasegawa,1 Miyuki Morozumi,1 Keisuke Sunakawa,3 and Kimiko Ubukata1*

Laboratory of Infectious Agents Surveillance, Kitasato Institute for Life Sciences and Graduate School of Infectious Control Sciences, Kitasato University, Shirokane, Minato-ku,1 and Laboratory of Electron Microscopy, Japan Women’s University, Mejirodai, Bunkyo-ku,2 Tokyo, and Department of Infectious Diseases, School of Medicine, Kitasato University, Kitasato, Sagamihara-shi, Kanagawa,3 Japan

Received 17 May 2004/Returned for modification 10 August 2004/Accepted 25 October 2004

The in vitro activity of tebipenem (TBM), a new oral carbapenem antibiotic, against Streptococcus pneumoniae clinical isolates (n = 202) was compared with those of 15 reference agents. The isolates were classified into five genotypic classes after PCR identification of abnormal pbp1a, pbp2x, and pbp2b genes: (i) penicillin-susceptible S. pneumoniae (PSSP) isolates with no abnormal pbp genes (n = 34; 16.8%), (ii) genotypic penicillin-intermediate S. pneumoniae (gPISP) isolates with only an abnormal pbp2x gene [gPISP (2x)] (n = 48; 23.8%), (iii) gPISP isolates with abnormal pbp1a and pbp2x genes (n = 32; 15.8%), (iv) gPISP isolates with abnormal pbp2x and pbp2b genes (n = 16; 7.9%), and (v) genotypic penicillin-resistant S. pneumoniae (gPRSP) isolates with three abnormal pbp genes (n = 72; 35.6%). The majority of the strains tested had mefA (n = 59; 29.2%) or ermB (n = 91; 45%) gene-mediating macrolide resistance. For these isolates the MIC at which 90% of isolates are inhibited was significantly lower for TBM than for the reference oral antibiotics, as follows: 0.002 μg/ml for PSSP, 0.004 μg/ml for gPISP (2x), 0.016 μg/ml for gPISP (isolates with abnormal pbp1a and pbp2x genes and isolates with abnormal pbp2x and pbp2b genes), and 0.063 μg/ml for gPRSP. In addition, TBM showed excellent bactericidal activity against gPRSP isolates, which exhibited a 3-log10 decrease within 2 h when they were incubated with a concentration greater than or equal to the MIC. Inhibition of cell wall synthesis toward the long axis and subsequent cell lysis were observed by scanning electron microscopy after a short-term exposure to TBM, unlike the effects seen with cephalosporins. These data suggest that TBM has potent activity against multidrug-resistant S. pneumoniae, the causative pathogen of community-acquired respiratory tract infections.

It is well known that carbapenem antibiotics have broad-spectrum activities and strong bactericidal actions against members of the family Enterobacteriaceae, Pseudomonas aeruginosa, and gram-positive cocci except methicillin-resistant Staphylococcus aureus and metallo-β-lactamase-producing pathogens. Four parenteral carbapenem agents, imipenem (14, 17), panipenem (24), meropenem (8, 28, 37), and biapenem (12), are used clinically in Japan as chemotherapeutic agents for the treatment of severe bacterial infections. However, no oral carbapenem antibiotic has yet been marketed. Tebipenem (TBM)-pivoxil (PI), a novel oral carbapenem agent with a 1-(1,3-thiazolin-2-yl) azetidin-3-ylthio group at the C-2 position, was developed by Wyeth Lederle Japan, Co. Ltd. (Tokyo, Japan). Phase II clinical studies of TBM-PI are now being conducted by Meiji Seika Kaisha, Ltd. (Tokyo, Japan), in Japan.

In this study, we evaluated the in vitro antibacterial and bactericidal activities of TBM against penicillin (PEN)-nonsusceptible Streptococcus pneumoniae isolates in comparison with those of 15 reference agents. The damage of PEN-resistant S. pneumoniae (PRSP) cells after exposure to TBM was also observed by scanning electron microscopy after a short-term exposure to TBM, unlike the effects seen with cephalosporins. These data suggest that TBM has potent activity against multidrug-resistant S. pneumoniae, the causative pathogen of community-acquired respiratory tract infections.

MATERIALS AND METHODS

Microorganisms and growth conditions. S. pneumoniae strains (n = 202) from clinical samples collected from pediatric patients with RTIs (n = 173), acute otitis media (n = 10), sepsis (n = 9), and meningitis (n = 10) were isolated in our laboratory between April 2002 and December 2002. The isolates were routinely grown on sheep blood agar II plates (Nippon Becton Dickinson, Tokyo, Japan) at 37°C in a 5% CO2 atmosphere. After several purifications, they were stored at −80°C in 10% skim milk (Difco Laboratories, Detroit, Mich.) for subsequent use. These isolates were identified as S. pneumoniae by PCR for the hsdA gene (9).

MIC determination. The MIC of each antibiotic was determined by the agar dilution method with cation-adjusted Mueller-Hinton (MH) agar (Difco Laboratories) supplemented with 5% defibrinated sheep blood (23). The size of the bacterial inoculum was adjusted to 108 CFU/spot by using bacteria precultured on blood agar II plates at 37°C in a 5% CO2 atmosphere for 18 h. The MIC was defined as the lowest antibiotic concentration which inhibited visible growth after 18 to 24 h of incubation. S. pneumoniae ATCC 49619 was used as a quality control strain for susceptibility testing.

Antibiotics. An active metabolite of TBM-PI synthesized at the Medical Research Laboratories, Wyeth Lederle Japan Co., Ltd., was supplied through Meiji...
Seika Kaisha, Ltd. Fifteen reference agents were obtained from the respective pharmaceutical companies: PEN, ampicillin (AMP), amoxicillin (AMX), and cefotetan (CDN) from Meiji Seika Kaisha, Ltd.; ceftolozane (CEC) and ceftazidime (CFN) from Shionogi Co., Ltd. (Osaka, Japan); cefdinir (CDR) from Fujisawa Pharmaceutical Co., Ltd. (Osaka, Japan); cefpodoxime (CPD) from Sankyo Co., Ltd. (Tokyo, Japan); faropenem (FRM) from Sunntory Ltd. (Osaka, Japan); clarithromycin (CLR) from Taisho-Toyama Pharmaceutical Co., Ltd. (Tokyo, Japan); azithromycin (AZM) from Pfizer Japan Inc. (Tokyo, Japan); telithromycin (TEL) from Aventis Pharma Ltd. (Tokyo, Japan); clindamycin (CLI) from Daiichi Pharmaceutical Co., Ltd. (Tokyo, Japan); and levofloxacin (LVX) from Daiichi Pharmaceutical Co., Ltd. (Tokyo, Japan).

Cefotaxime (CTX) was obtained from Chugai Pharmaceutical Co., Ltd., and was used as the standard reference for intravenous agents.

**PCR conditions.** Abnormal *pbp* genes encoding PBP 1A (3, 19, 27), PBP 2X (4, 18, 25), and PBP 2B (6, 36) were detected by PCR. The conditions and primers used in this study are those described previously (22, 33). Each PEN-binding protein (PBP) gene was amplified only from strains with the same *pbp1a*, *pbp2x*, and *pbp2b* gene sequences as susceptible strain R6 at the primer binding sites. These sites were positioned in blocks of highly diverged sequences and in the sequence of conserved amino acids motifs, such as Ser-Thr-Met-Lys of the *pbp1a* gene in PRSP strains. On the basis of the PCR results, the strains tested were classified into five groups according to their *pbp* genotypes, as follows: (i) PEN-susceptible *S. pneumoniae* (PSSP) isolates with three normal *pbp* genes, (ii) genotypic PEN-intermediate *S. pneumoniae* (gPISP) isolates with abnormal *pbp2x* genes [gPISP (2x)], (iii) gPISP isolates with abnormal *pbp1a* and *pbp2x* genes, (iv) gPISP isolates with abnormal *pbp2x* and *pbp2b* genes, and (v) genotypic PRSP (gPRSP) isolates with three abnormal *pbp* genes.

In addition, the *ermB* (30) and *mefA* (26, 29) genes, which mediate macrolide resistance, were detected by PCR, together with the *pbp* and the *b-ha* genes (31, 32).

**Killing kinetics.** Time-kill curves of TBM and reference antibiotics for JPS240 (serotype 6B) and ME19 (serotype 19F) strains of PRSP were determined at concentrations corresponding to the MIC, two times the MIC, and four times the MIC for each strain. A bacterial suspension (500 μl) in MH broth supplemented with 5% defibrinated sheep blood was grown at 37°C for 3 h and was then inoculated into 9.5 ml of fresh MH broth containing each of the antibiotics to be tested and 5% sheep blood. The tubes were then incubated without shaking, and the cultures were sampled at predetermined intervals. The samples were serially diluted 10-fold with MH broth, and 100 μl of each diluted sample was plated in triplicate on blood agar plates. The numbers of colonies that grew on the blood agar plates were counted after incubation at 37°C in a 5% CO₂ atmosphere for 20 h.

**RESULTS**

**Activity of TBM against S. pneumoniae.** Table 1 shows the activities of TBM and 10 reference β-lactam antibiotics against *S. pneumoniae* isolates obtained from pediatric patients with RTIs, acute otitis media, sepsis, and meningitis. Figure 2 shows the distributions of the susceptibilities of these isolates to TBM according to their genotypes. All strains were classified into five genotypic classes according to the presence of abnormal *pbp* genes, namely, *pbp1a*, *pbp2x*, and *pbp2b*, as identified by PCR: (i) PSSP isolates with no abnormal *pbp* gene (n = 34; 16.8%); (ii) gPISP (2x) isolates with an abnormal *pbp2x* gene (n = 48; 23.8%); (iii) gPISP isolates with abnormal *pbp1a* and *pbp2x* genes (n = 32; 15.8%); (iv) gPISP isolates with abnormal *pbp2x* and *pbp2b* genes (n = 16; 7.9%); and (v) gPRSP isolates with abnormal *pbp1a*, *pbp2x*, and *pbp2b* genes (n = 72; 35.6%).

The MIC range, the MIC at which 50% of isolates are inhibited (MIC₅₀), and the MIC₉₀ of TBM for the PSSP, gPISP (2x), gPISP, and gPRSP isolates indicated that TBM had stronger antibacterial activities than the other antibiotics. The MIC₉₀ₙg for the gPISP isolates were as follows: TBM, 0.063 μg/ml; FRM, 0.5 μg/ml; CTX, CDN, and CFN, 1 μg/ml; PEN, AMP, and AMX, 2 μg/ml; CPD, 4 μg/ml; CDR, 8 μg/ml; and

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>PSSP (n = 34)</th>
<th>gPISP (n = 48)¹</th>
<th>gPISP (n = 48)²</th>
<th>gPRSP (n = 72)³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Range</td>
<td>50%</td>
<td>90%</td>
<td>50%</td>
<td>90%</td>
</tr>
<tr>
<td>T ebenem</td>
<td>&lt;0.001–0.004</td>
<td>0.002</td>
<td>0.002</td>
<td>0.002–0.016</td>
</tr>
<tr>
<td>Penicillin G</td>
<td>0.008–0.063</td>
<td>0.016</td>
<td>0.031</td>
<td>0.031–0.375</td>
</tr>
<tr>
<td>Ampicillin</td>
<td>0.008–0.031</td>
<td>0.016</td>
<td>0.031</td>
<td>0.031–0.5</td>
</tr>
<tr>
<td>Amoxicillin</td>
<td>0.008–0.063</td>
<td>0.016</td>
<td>0.031</td>
<td>0.031–0.633</td>
</tr>
<tr>
<td>Cefotaxime</td>
<td>0.008–0.25</td>
<td>0.016</td>
<td>0.125</td>
<td>0.125</td>
</tr>
<tr>
<td>Cefaclor</td>
<td>0.25–1</td>
<td>0.5</td>
<td>1</td>
<td>0.5–8</td>
</tr>
<tr>
<td>Cefpodoxime</td>
<td>0.016–0.5</td>
<td>0.031</td>
<td>0.25</td>
<td>0.063–1</td>
</tr>
<tr>
<td>Cefdinir</td>
<td>0.031–0.25</td>
<td>0.063</td>
<td>0.25</td>
<td>0.063</td>
</tr>
<tr>
<td>Cefditoren</td>
<td>0.004–0.063</td>
<td>0.008</td>
<td>0.031</td>
<td>0.016–0.25</td>
</tr>
<tr>
<td>Cefcapene</td>
<td>0.004–0.25</td>
<td>0.008</td>
<td>0.125</td>
<td>0.031–0.5</td>
</tr>
<tr>
<td>Faropenem</td>
<td>0.008–0.016</td>
<td>0.008</td>
<td>0.008</td>
<td>0.008–0.063</td>
</tr>
</tbody>
</table>

¹ Clinical isolates of *S. pneumoniae* that have an abnormal *pbp2x* gene.

² Clinical isolates that have abnormal *pbp2x* and *pbp2b* or *pbp1a* and *pbp2x* genes.

³ Clinical isolates that have three abnormal *pbp* genes: *pbp1a*, *pbp2x*, and *pbp2b*.
CEC, 64 μg/ml. Of these β-lactam agents, CPD, CDR, FRM, CDN, and CFN were developed by Japanese pharmaceutical companies and are marketed mainly in Japan.

Namely, TBM was very active against the isolates tested, with MICs of 0.002 to 0.031 μg/ml for the gPISP isolates and 0.016 to 0.125 μg/ml for the gPRSP isolates. The MICs of TBM ranged from ≤0.001 to 0.004 μg/ml for all PSSP and gPISP (2x) isolates except one strain that had two amino acid substitutions in Ser-Thr-Met-Lys (STMK) of the conserved motif.

Table 2 shows the MIC ranges, MIC<sub>50</sub> and MIC<sub>90</sub> of CLR, AZM, TEL, CLI, and LVX for <i>S. pneumoniae</i> strains. The frequencies at which strains possessed the <i>mefA</i> and the <i>ermB</i> genes were 29.2% (n = 59) and 45% (n = 91), respectively.

The MIC<sub>90</sub> for all strains were as follows: TEL, 0.125 μg/ml; LVX, 2 μg/ml; and CLR, AZM, and CLI, 64 μg/ml.

**Killing kinetics.** Figure 3 shows the time-kill curves for TBM and the reference β-lactam antibiotics (AMP, CDN, CDR, CFN, and FRM) at concentrations corresponding to the MIC, two times the MIC, and four times the MIC for PRSP strain JPS240 (serotype 6B). This strain was isolated from the cerebrospinal fluid of a pediatric patient with meningitis.

Unlike the five reference antibiotics, TBM exhibited an apparent bactericidal effect at concentrations higher than the MIC. TBM showed the strongest bactericidal activity as early as 2 h after exposure at two times the MIC, followed by AMP and FRM (4 h at two times the MIC), CDN and CFN (6 h at two times the MIC), and CDR (>6 h at two times the MIC), with the reduction being on the order of 3 log units of viable cells.

The bactericidal activity of TBM against PRSP strain ME19 (serotype 19F) was similar to that against PRSP strain JPS240 (data not shown).

**Morphological changes.** Figure 4 shows the morphological changes of PRSP ME19 cells following exposure to TBM at the MIC and two times the MIC and reference antibiotic CDN at the MIC for 2 h. These observations were made under an LV scanning electron microscope. As shown for the control cells (Fig. 4A), we presumed that the homogeneous protrusions on the spongiform surface were part of the cell wall. We also considered that the cell wall synthesis toward the long axis occurred in the shape of a coil paralleling a septum, because protrusions were observed in a parallel arrangement with the septum.

Cell wall synthesis stopped in the pneumococcal cells exposed to TBM at 0.063 μg/ml (the MIC) and 0.125 μg/ml (two times the MIC) for 2 h, and the protrusions were pulled in the direction of the long axis with the swelling of the cell (Fig. 4B). After that, cell lysis was observed from the sites considered to be fragile (Fig. 4B and C). The effect of exposure for more than 4 h could not be examined by SEM because of complete cell lysis.

With exposure to cephalosporins, such as CDN (Fig. 4D), cell lysis occurred following marked cell elongation due to the inhibition of septum formation.

**DISCUSSION**

Severe infections caused by PEN-nonsusceptible <i>S. pneumoniae</i> and/or macrolide-antibiotic resistant isolates have been
a matter of concern worldwide (1, 13, 15). In Japan, much attention has been given to the increased incidence of PEN-nonsusceptible *S. pneumoniae* since the late 1980s (2). Now, the incidence of these isolates is higher in Japan than in the United States and Europe (31, 34).

One conceivable reason for this may be differences in the rates of use of oral antibiotics by outpatients in different countries. In the 1980s in Japan, attention was focused on β-lactamase-producing pathogens; therefore, many oral cephalosporin antibiotics with an amino-thiazol side chain at position 7 were developed. Regrettably, the development of those agents took place before PEN-nonsusceptible *S. pneumoniae* isolates became prevalent (10, 35). Consequently, their clinical efficacies for the treatment of RTIs caused by PISP and PRSP isolates were not evaluated correctly. Although the clinical efficacies of cephalosporin antibiotics for pneumococcal infections refer to the parameter time above the MIC (7), the concentrations of new oral cephalosporins in serum are usually low, ranging from 0.5 to 1.5 μg/ml after the administration of a single dose of 100 mg in adults.

From the background presented above, the development of new oral β-lactam antibiotics with excellent bactericidal activities against PRSP and high degrees of bioavailability has been expected in Japan. TBM, which is under development in Japan, is one of the new carbapenem antibiotics expected to fulfill such requirements. The prominent feature of TBM is its potent activity against the main causative microorganisms, except metallo-β-lactamase-producing pathogens and methicillin-resistant *S. aureus* strains, in outpatients with RTIs and UTIs (11, 20).

As for PBPs related to β-lactam resistance in *S. pneumoniae*, TBM shows higher affinities for PBP 1A and PBP 2B, high-molecular-weight enzymes, and for PBP 3, a low-molecular-weight enzyme, than for PBP 2X (11).

As shown in Results, in addition to the excellent MIC₉₀ of TBM for PISP and PRSP isolates, strong bactericidal activity accompanied by cell lysis was observed within a short time after exposure to TBM at a concentration equal to or greater than the MIC. These results may be caused by its unique affinity for PBPs. Moreover, this bactericidal action might be reflected in the efficacy of TBM observed in a murine pneumonia model (20).

As Craig (5) stated, the time above the MIC is generally believed to be the major pharmacokinetic-pharmacodynamic parameter determining the in vivo efficacies of β-lactams, unlike aminoglycosides and fluoroquinolones. However, in the TBM study using a mouse PRSP infection model, a high correlation was observed between the in vivo efficacy and the maximum concentration of drug in plasma/MIC or the area under the concentration-time curve/MIC rather than the time above the MIC as a pharmacokinetic-pharmacodynamic parameter (Meiji Seika Kaisha, Ltd., personal communication). The great difference between these results and common knowl-

![FIG. 3. Kinetic curves of bacterial killing by TBM and the other five β-lactam antibiotics at the MICs (●), two times the MICs (▲), and four times the MICs (■) for PRSP strain JPS240 (serotype 6B). ○, control (no drug).](http://aac.asm.org/.../2017 by guest)
edge about β-lactam antibiotics is probably due to the strong bactericidal activity of TBM described in the study (21).

Phase I clinical studies have already been conducted with TBM. The values of the pharmacokinetic parameters for TBM after the administration of a single dose of 150 mg to healthy volunteers were as follows: 5.85 ± 2.35 μg/ml for the maximum concentration of drug in plasma, 0.58 ± 0.42 h for the time to the maximum concentration of drug in plasma, 0.50 ± 0.26 h for the half-life, 5.57 ± 1.08 μg·h/ml for the area under the concentration-time curve, and 73.4% ± 6.7% for urinary excretion within 6 h.

Phase II clinical studies with adult patients are in progress. The bacteriological effects of TBM against PRSP presented in this study will be clarified through the analysis of data from phase II clinical studies in the near future.

FIG. 4. Morphological changes to S. pneumoniae ME19 (serotype 19F) cells (A) after exposure to TBM at its MIC (0.063 μg/ml) (B) and two times its MIC (0.125 μg/ml) (C) and CDN at its MIC (0.5 μg/ml) (D). Cells were observed with a scanning electron microscope (model S-900H; Hitachi). Each bar indicates 1 μm.


